Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Lapatinib	
INITIATION Prerequisites (tick box where appropriate) O For continuation use only	
CONTINUATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)	
The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) and The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib and	
Lapatinib not to be given in combination with trastuzumab and Lapatinib to be discontinued at disease progression	

I confirm that the above details are correct:	
Signed:	Date: